ArticleCancer management and research2018
Pooling analysis on prognostic value of PHH3 expression in cancer patients.
Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Evaluation of Phosphohistone H3 in Assessment of Mitotic Activity in Invasive Breast Carcinoma: A Correlative Study With Ki-67 and Histologic Grade.International journal of surgical pathology · 2026Article
- Expression of phosphohistone H3 and X-linked inhibitors of apoptosis-related proteins in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary glands.Scientific reports · 2025Article
- Establishment of the Prognostic Signature with Genes Related to G2/M Checkpoint in Hepatocellular Carcinoma.Biochemical genetics · 2025Article
- Potential of Proliferative Markers in Pancreatic Cancer Management: A Systematic Review.Health science reports · 2025Review
- Vitamin D and Mitosis Evaluation in Endometriosis: A Step toward Discovering the Connection?Biomedicines · 2023Article
- Hyperactive CREB subpopulations increase during therapy in pediatric B-lineage acute lymphoblastic leukemia.Haematologica · 2023Article
- The value of Phosphohistone H3 as a cell proliferation marker in oral squamous cell carcinoma. A comparative study with Ki-67 and the mitotic activity index.Medicina oral, patologia oral y cirugia bucal · 2022Article
- The prognostic importance of PD-L1, PTEN, PHH3, and KI-67 expressions in invasive breast carcinoma.Revista da Associacao Medica Brasileira (1992) · 2022Article
- Mitotic Activity in Gastrointestinal Stromal Tumors: Can we use Phosphohistone H3 Immunohistochemistry Instead of Hematoxylin and Eosin for Mitotic Count?Sisli Etfal Hastanesi tip bulteni · 2022Article
- Ki67 as a prognostic factor of craniopharyngioma's recurrence in paediatric population.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVarious studies have evaluated the significance of phosphohistone-H3 (PHH3) expression in cancer patients, but controversy over its reliability remains. We conducted a meta-analysis to summarize the prognostic relevance of PHH3 expression in cancer patients. PATIENTS AND
methodsNineteen studies, including 4803 patients, were identified by searching PubMed, Web of Science, Embase, and Cochrane Library. The correlation of PHH3 expression level with overall survival (OS), disease-free survival, and recurrence-free survival was analyzed.
resultsOverall, the results suggest that high expression of PHH3 can predict a poor OS (HR=2.66, 95% CI=1.74-4.08,
conclusionThis meta-analysis indicates that high expression of PHH3 may serve as a biomarker for poor prognosis in patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.